UB Paderborn / Katalog / Suche / in CDI

Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients

Supportive care in cancer, 2021-11, Vol.29 (11), p.6633-6643

2021

Volltextzugriff (PDF)

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project

Breast cancer research and treatment, 2019-06, Vol.175 (3), p.701-712

2019

Volltextzugriff (PDF)

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR

Current medical research and opinion, 2019-07, Vol.35 (7), p.1127-1138

2019

Volltextzugriff (PDF)

Similar effectiveness of R‐CHOP‐14 and ‐21 in diffuse large B‐cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms

European journal of haematology, 2019-11, Vol.103 (5), p.460-471

2019

Volltextzugriff (PDF)

Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR

Current medical research and opinion, 2022-12, Vol.38 (12), p.2191-2199

2022

Volltextzugriff (PDF)

Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO

Clinical breast cancer, 2020-06, Vol.20 (3), p.e315-e326

2020

Volltextzugriff (PDF)

Persistent impairments 3 years after

Breast cancer research and treatment, 2017-10, Vol.165 (3), p.721

2017

Volltextzugriff (PDF)

An observational study to evaluate the potential of Onlife to improve chemotherapy-induced peripheral neuropathy: Final results of the STEFANO trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e23143-e23143

2019

Volltextzugriff (PDF)

Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel

Clinical breast cancer, 2018-12, Vol.18 (6), p.e1323-e1337

2018

Volltextzugriff (PDF)

Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial

International journal of cancer, 2021-04, Vol.148 (7), p.1685-1694

2021

Volltextzugriff (PDF)

Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials—Analyses From the German Clinical RCC Registry

Clinical genitourinary cancer, 2017-04, Vol.15 (2), p.e209-e215

2017

Volltextzugriff (PDF)

Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO

Oncology research and treatment, 2021-11, Vol.44 (11), p.613-621

2021

Volltextzugriff (PDF)

Routine clinical use of nab -paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12555-e12555

2017

Volltextzugriff (PDF)

Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project

Breast cancer research and treatment, 2017-10, Vol.165 (3), p.721-731

2017

Volltextzugriff (PDF)

Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials

Leukemia research, 2018-05, Vol.68, p.90-97

2018

Volltextzugriff (PDF)

Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5546-5546

2018

Volltextzugriff (PDF)

1st-Line Treatment with R-CHOP-14 or R-CHOP-21 in Patients with High-Grade Non-Hodgkin’s Lymphoma Is Similarly Effective: Data from the German Prospective TLN Registry

Blood, 2014-12, Vol.124 (21), p.4406-4406

2014

Volltextzugriff (PDF)

Prophylaxis of chemotherapy‐induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non‐Hodgkin lymphoma (NADIR study)

European journal of haematology, 2019-02, Vol.102 (2), p.174-181

2019

Volltextzugriff (PDF)

Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study)

European journal of haematology, 2018-12, Vol.101 (6), p.766-773

2018

Volltextzugriff (PDF)

Response To 1st-Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry

Blood, 2013-11, Vol.122 (21), p.4181-4181

2013

Volltextzugriff (PDF)

Response To 1st-Line Treatment With BR Or R-CHOP In Patients With Indolent Non-Hodgkin's Lymphoma: First Outcome Data From The German Prospective TLN Registry

Blood, 2013-11, Vol.122 (21), p.3036-3036

2013

Volltextzugriff (PDF)

Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from clinical trials - Analyses from the German clinical RCC Registry

Clinical genitourinary cancer, 2016

2016

Volltextzugriff (PDF)

NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis

Oncology research and treatment, 2015-05, Vol.38 (5), p.221-229

2015

Volltextzugriff (PDF)

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task

European journal of cancer (1990), 2019-05, Vol.113, p.47-54

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients

Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR

Similar effectiveness of R‐CHOP‐14 and ‐21 in diffuse large B‐cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms

Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR

Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO

Persistent impairments 3 years after

An observational study to evaluate the potential of Onlife to improve chemotherapy-induced peripheral neuropathy: Final results of the STEFANO trial

Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel

Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial

Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials—Analyses From the German Clinical RCC Registry

Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO

Routine clinical use of nab -paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO

Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project

Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials

Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts

1st-Line Treatment with R-CHOP-14 or R-CHOP-21 in Patients with High-Grade Non-Hodgkin’s Lymphoma Is Similarly Effective: Data from the German Prospective TLN Registry

Prophylaxis of chemotherapy‐induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non‐Hodgkin lymphoma (NADIR study)

Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study)

Response To 1st-Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry

Response To 1st-Line Treatment With BR Or R-CHOP In Patients With Indolent Non-Hodgkin's Lymphoma: First Outcome Data From The German Prospective TLN Registry

Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from clinical trials - Analyses from the German clinical RCC Registry

NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task

Suchergebnisse filtern